ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 65 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 65 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $179.00, for a total value of $11,635.00. Following the transaction, the director directly owned 4,871 shares of the company’s stock, valued at $871,909. This represents a 1.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

ICU Medical Price Performance

NASDAQ:ICUI traded up $1.97 during mid-day trading on Friday, reaching $179.27. 195,454 shares of the stock were exchanged, compared to its average volume of 278,884. The company has a current ratio of 2.37, a quick ratio of 1.19 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average price of $163.72 and a 200 day moving average price of $149.91. ICU Medical, Inc. has a 1-year low of $113.37 and a 1-year high of $192.85. The firm has a market capitalization of $4.48 billion, a PE ratio of 75.01, a PEG ratio of 2.23 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. The company had revenue of $556.22 million during the quarter, compared to the consensus estimate of $552.03 million. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. ICU Medical’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.03 EPS. Research analysts expect that ICU Medical, Inc. will post 7.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ICUI shares. BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Raymond James Financial reissued a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a research note on Friday, August 7th. Piper Sandler boosted their price objective on ICU Medical from $195.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Needham & Company LLC lifted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.20.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. Allworth Financial LP acquired a new position in shares of ICU Medical during the 2nd quarter worth about $26,000. Global Retirement Partners LLC boosted its stake in ICU Medical by 203.4% during the 3rd quarter. Global Retirement Partners LLC now owns 179 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 120 shares during the period. Bessemer Group Inc. grew its holdings in ICU Medical by 65.8% in the 3rd quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 75 shares during the last quarter. Hantz Financial Services Inc. increased its position in ICU Medical by 78.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 105 shares during the period. Finally, Versant Capital Management Inc increased its position in ICU Medical by 26.2% in the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 65 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.